Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

07-413

Sigma-Aldrich

Anti-dimethyl-Arginine Antibody, symmetric (SYM11)

Upstate®, from rabbit

Synonyma:

Anti-SYM11, Anti-dimethyl-Arginine, Symmetric Dimethyl-Arginine Ab

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

100

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human, mouse

manufacturer/tradename

Upstate®

technique(s)

western blot: suitable

isotype

IgG

shipped in

dry ice

target post-translational modification

unmodified

General description

Symmetrical dimethylated arginine (sDMA) is a product of the post-translational modification, arginine methylation. sDMA is a structural isomer of asymmetric dimethylarginine.

Specificity

SmD3 at ~16kDa, and other proteins that contain arginines that are symmetrically dimethylated

Immunogen

peptide corresponding to amino acids 99-119 of Small nuclear ribonucleoprotein SmD3.

Application

Anti-dimethyl-Arginine Antibody, symmetric (SYM11) has been used in:
  • co-immunoprecipitation (co-IP)
  • western blot analysis
  • immunoprecipitation

Biochem/physiol Actions

Symmetrical dimethylarginine (sDMA) is a competitor of arginine transport and is eliminated through renal excretion. sDMA serves as a marker to indicate the estimated glomerular filtration rate (GFR) and the coronary artery disease (CAD) severity. Elevated sDMA is associated with the risk of cardiovascular disease and mortality. It might also help in the early detection of chronic kidney disease. sDMA acts as an endogenous marker of renal function. It is associated with tumorigenesis.

Quality

routinely evaluated by immunoblot in RIPA lysates from Jurkat cells

Target description

~16 kDa

Physical form

Format: Purified

Analysis Note

Control
Positive Antigen Control: Catalog #12-303, Jurkat cell lysate.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Ještě jste nenalezli správný produkt?  

Vyzkoušejte náš produkt Nástroj pro výběr produktů.

Storage Class

10 - Combustible liquids

wgk_germany

WGK 1

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Rui Liu et al.
Microbiology spectrum, 11(6), e0290623-e0290623 (2023-10-26)
PRMT5 contributes to secondary metabolite biosynthesis in Ganoderma lucidum. However, the mechanism through which PRMT5 regulates the biosynthesis of secondary metabolites remains unclear. In the current study, PRMT5 silencing led to a significant decrease in the biosynthesis of polysaccharides from
Jérémy Dufourt et al.
Nature communications, 8(1), 1305-1305 (2017-11-05)
Piwi-interacting RNAs (piRNAs) and PIWI proteins play a crucial role in germ cells by repressing transposable elements and regulating gene expression. In Drosophila, maternal piRNAs are loaded into the embryo mostly bound to the PIWI protein Aubergine (Aub). Aub targets
Zi Wang et al.
Communications biology, 7(1), 241-241 (2024-02-29)
PRMT5, a type II arginine methyltransferase, is involved in transcriptional regulation, RNA processing and other biological processes and signal transduction. Secondary metabolites are vital pharmacological compounds in Ganoderma lucidum, and their content is an important indicator for evaluating the quality
Ming Gao et al.
EMBO reports, 16(3), 379-386 (2015-01-21)
Germ cells give rise to all cell lineages in the next-generation and are responsible for the continuity of life. In a variety of organisms, germ cells and stem cells contain large ribonucleoprotein granules. Although these particles were discovered more than
Christopher R Smith et al.
Journal of medicinal chemistry, 65(3), 1749-1766 (2022-01-19)
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery of development candidate MRTX1719. MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.